熱門資訊> 正文
Ascendis和Royalty Pharma达成1.5亿美元的特许权使用费融资协议
2024-09-04 05:17
- Ascendis Pharma (ASND) and Royalty Pharma (NASDAQ:RPRX) said on Tuesday that Ascendis Pharma Bone Diseases, a subsidiary of Ascendis has entered into a $150M royalty funding agreement with Royalty Pharma based on U.S. net sales of YORVIPATH.
- Under the terms of the agreement, Ascendis (ASND) receives an upfront payment of $150M in exchange for a 3% royalty on U.S. net sales of YORVIPATH.
- The royalty payments to Royalty Pharma (RPRX) will cease upon reaching a multiple of 2.0x, or 1.65x if Royalty Pharma receives royalties in that amount by December 31, 2029.
More on Ascendis Pharma, Royalty Pharma, etc.
- Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
- Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up
- Royalty Pharma: Busy Putting Capital To Work
- Ascendis Pharma Q2 2024 Earnings Preview
- Ascendis Pharma Q2 2024 Earnings Preview
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
